https://european-biotechnology.com/wp-content/uploads/2024/04/Pierre_Guerin_site.jpg450800Maren Kühr/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngMaren Kühr2018-04-16 00:00:002018-04-16 00:00:00New Pierre Guerin site in Hildesheim, Germany
https://european-biotechnology.com/wp-content/uploads/2024/04/Alexandra_Pearce.jpg321321h.genrich/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngh.genrich2018-04-13 17:01:002018-04-13 17:01:00Abivax appoints Alexandra Pearce as VP of Regulatory Affairs
British drug major GlaxoSmithKline (GSK) has passed its orphan autologous cell and gene therapy pipeline including its EU-approved ADA-SCID treatment Strimvelis to British/US Orchard Therapeutics. GSK acquired a 19,9% equity stake in Orchard and a board membership.
A public offer from orphan drug major Alexion Pharmaceuticals Inc. has been accepted by Wilson Therapeutics Board of Directors. Alexions SEK232/share bid would total in an acqusition price of SEK6.564bn or €638.8m.
https://european-biotechnology.com/wp-content/uploads/2024/04/Bildschirmfoto_2018-04-11_um_09.44.48.png268721Thomas Gabrielczyk/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngThomas Gabrielczyk2018-04-11 08:44:062018-04-11 08:44:06Alexion in €639m bid for Wilson Therapeutics AB
The Eppendorf DASbox mini bioreactor system with its small working volume, compact design, as well as advanced control, and information management options is ideal for research and early development processes.
https://european-biotechnology.com/wp-content/uploads/2024/04/DASbox.jpg9001600Maren Kühr/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngMaren Kühr2018-04-10 11:55:072024-04-02 15:51:43DASbox® Mini Bioreactor System: Most Compact System for Early Stage Processes
Swiss drug major Novartis has secured a potential stake in the multibillion dollar market of treatments for the orphan genetic muscle disease spinal muscular atrophy (SMA). The company acquired AveXis Inc, whose SMA gene therapy AVXS-101 is in Phase III testing.
Commense, Inc., an affiliate of PureTech Health plc developing microbiome-derived immune modulators for paediatric and maternal health, today announced the appointment of Edward J. Tad Stewart as President and Chief Executive Officer.
https://european-biotechnology.com/wp-content/uploads/2024/04/EB_Appointments_TadStewart_Commense_CEO.png400400h.genrich/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngh.genrich2018-04-09 14:36:482018-04-09 14:36:48Commense Appoints Edward J. Stewart as President and CEO
https://european-biotechnology.com/wp-content/uploads/2024/04/DKFZ_Altzheimer.jpg517743Thomas Gabrielczyk/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngThomas Gabrielczyk2018-04-09 08:01:342018-04-09 08:01:34Blood test predincting Alzheimer’s paves way to earlier therapy
Human drug trials are compromised by poor reporting and potential bias of animal research. German researchers analysed more than 700 preclinical animal studies and investigator brochures provided by three medical centres. They call to establish documentation standards for IBs/preclinical dossiers.
Nordic Nanovector ASA announces that Luigi Costa will step down as Chief Executive Officer by mutual agreement with the Board of Directors. A search for a new CEO will begin immediately. To ensure a smooth transition, Mr Costa has agreed to be available to the board until the end of July 2018.
https://european-biotechnology.com/wp-content/uploads/2024/04/app_Luigi_Costa.jpg245245h.genrich/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngh.genrich2018-04-05 13:32:422018-04-05 13:32:42Nordic Nanovector’s Luigi Costa to step down as CEO
New Pierre Guerin site in Hildesheim, Germany
Latest NewsMid last year, the company Pierre Guerin has opened a new location in Germany, Hildesheim.
Abivax appoints Alexandra Pearce as VP of Regulatory Affairs
AppointmentsDr. Pearce Joins as ABIVAX Works with FDA and EMA on Next Stage Developments of its Clinical Product Candidates
GSK pass orphan gene therapy assets to Orchard Therapeutics
Latest NewsBritish drug major GlaxoSmithKline (GSK) has passed its orphan autologous cell and gene therapy pipeline including its EU-approved ADA-SCID treatment Strimvelis to British/US Orchard Therapeutics. GSK acquired a 19,9% equity stake in Orchard and a board membership.
Alexion in €639m bid for Wilson Therapeutics AB
Latest NewsA public offer from orphan drug major Alexion Pharmaceuticals Inc. has been accepted by Wilson Therapeutics Board of Directors. Alexions SEK232/share bid would total in an acqusition price of SEK6.564bn or €638.8m.
DASbox® Mini Bioreactor System: Most Compact System for Early Stage Processes
ProductsThe Eppendorf DASbox mini bioreactor system with its small working volume, compact design, as well as advanced control, and information management options is ideal for research and early development processes.
Novartis enters SMA race acquiring AveXis for US$8.7bn
Latest NewsSwiss drug major Novartis has secured a potential stake in the multibillion dollar market of treatments for the orphan genetic muscle disease spinal muscular atrophy (SMA). The company acquired AveXis Inc, whose SMA gene therapy AVXS-101 is in Phase III testing.
Commense Appoints Edward J. Stewart as President and CEO
AppointmentsCommense, Inc., an affiliate of PureTech Health plc developing microbiome-derived immune modulators for paediatric and maternal health, today announced the appointment of Edward J. Tad Stewart as President and Chief Executive Officer.
Blood test predincting Alzheimer’s paves way to earlier therapy
Latest NewsA newly developed blood test indicates Alzheimer’s disease on average eight years before the clinical diagnosis.
Poor investigator brochures: Resarchers call for standardisation
Latest NewsHuman drug trials are compromised by poor reporting and potential bias of animal research. German researchers analysed more than 700 preclinical animal studies and investigator brochures provided by three medical centres. They call to establish documentation standards for IBs/preclinical dossiers.
Nordic Nanovector’s Luigi Costa to step down as CEO
AppointmentsNordic Nanovector ASA announces that Luigi Costa will step down as Chief Executive Officer by mutual agreement with the Board of Directors. A search for a new CEO will begin immediately. To ensure a smooth transition, Mr Costa has agreed to be available to the board until the end of July 2018.